BN Business News
Add your company to Business Communicator →

Business · 26/06/2026Updated: 10/17/2026 · 1 min read

FDA Extends Comment Period for 503B Bulks List Proposal

Summary

The FDA is extending the comment period for its proposal not to include semaglutide, tirzepatide, or liraglutide on a list of bulk drug substances for outsourcing compounding facilities, in response to a request for an extension from interested persons.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Explore insights

Business insights →